News
05-18-2011, 10:40 PM
Nektar Therapeutics today announced that new Phase 2 clinical data for NKTR-102, Nektar's lead oncology candidate being evaluated in multiple cancer indications, have been selected for presentation at the 47th Annual Meeting of the American Society of Clinical Oncology being held June 3-7, 2011 in Chicago, Illinois.
More... (http://www.news-medical.net/news/20110519/Nektar-to-present-new-NKTR-102-Phase-2-clinical-data-in-multiple-cancer-at-ASCO-annual-meeting.aspx)
More... (http://www.news-medical.net/news/20110519/Nektar-to-present-new-NKTR-102-Phase-2-clinical-data-in-multiple-cancer-at-ASCO-annual-meeting.aspx)